Ibogaine Dosage Control for Anxiety and Impulse Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anxiety disorders, impulse control disorders, anger/violence-related disorders, and obesity regulation using ibogaine are hindered by the risk of QT interval prolongation and the need for effective, safe dosing protocols that do not cause fatal hallucinations at high doses.
Innovation Solution
Administering a narrow dosage range of ibogaine between 1 mg/kg and 4 mg/kg, with specific subranges for therapeutic effects and minimal QT interval prolongation, and using direct bloodstream delivery methods like sublingual, pulmonary, or intranasal administration to enhance brain absorption and reduce symptoms rapidly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of ibogaine are administered to treat addiction and psychiatric disorders, then therapeutic effects are improved, but the risk of QT interval prolongation and fatal hallucinations increases
Solution Approach 1:
The patent applies parameter changes by precisely adjusting the ibogaine dosage to a narrow therapeutic window (1-4 mg/kg body weight). This specific dosage range was determined to provide adequate therapeutic effects for addiction and psychiatric disorders while minimizing the risk of QT interval prolongation and fatal hallucinations associated with higher doses.
Solution Approach 2:
The patent employs partial action by administering a sub-maximal dose of ibogaine that is sufficient to achieve therapeutic effects without reaching the excessive dosage levels that cause harmful side effects. The dosage is carefully calibrated to provide just enough pharmacological activity to treat the disorder while staying below the threshold for toxic effects.
2Object-affected harmful factors
If a narrow dosage range of ibogaine is administered to minimize QT interval prolongation, then safety is improved, but the therapeutic effectiveness may be reduced
Solution Approach 1:
The patent resolves this contradiction by identifying and applying the optimal dosage parameters (1-4 mg/kg body weight) that simultaneously achieve therapeutic effectiveness and minimize QT interval prolongation. Through careful parameter optimization, the patent demonstrates that adequate therapeutic response can be obtained within this narrow safety window.
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring patient response and cardiac parameters (QT interval) to adjust and maintain dosing within the therapeutic window. This feedback approach ensures that therapeutic effectiveness is achieved while continuously preventing QT interval prolongation by adjusting dosage based on individual patient response.
3Speed
If direct bloodstream delivery methods (sublingual, pulmonary, intranasal) are used to enhance brain absorption, then speed of action is improved, but the risk of rapid onset side effects increases
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage amount administered through direct bloodstream delivery methods. Since these routes provide rapid absorption, the patent uses lower dosage amounts within the 1-4 mg/kg range to achieve the same therapeutic effect while preventing rapid onset of side effects that could occur with higher doses delivered through the same fast-absorbing routes.
Data Source
AI summary
This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.